HIFU

Blocking prostate cancer cells metabolism with drug therapy may inhibit growth

For years, attempts have been made to understand the mechanism behind the proliferation of cancer cells: they need metabolites to grow and proliferate as much as a vehicle needs gasoline or electricity to move. However, until now it was not known which metabolites cancer cells actually need. A team of researchers from the Institute of Oncology Research (IOR) at the Università della Svizzera Italiana (USI, Faculty of Biomedical Sciences) led by Prof. Andrea Alimonti has identified one of the mechanisms behind this process, as published in a recent article in the journal Nature Genetics. From a theory dating back to the early 20th century by Nobel Prize laureate Otto Warburg, it has been believed that, in order to support their growth, cancer cells needed [...]

2018-02-13T09:06:03+00:00February 13th, 2018|

Cancerous tissue discernible from healthy tissue in prostate cancer patients

Using nuclear medicine, researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research demonstrates that the maximum standardized uptake value (SUVmax) on 68Ga-PSMA PET/CT scans correlates with PSMA-expression in primary prostate cancer. By this means, researchers were able to generate an SUVmax cutoff for the differentiation of cancerous and benign prostate tissue. Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in the February issue of The Journal of Nuclear Medicine. According to the American Cancer Society, one in nine men will be diagnosed with prostate cancer in his lifetime. Early diagnosis is key to successful treatment. The new [...]

2018-02-06T08:27:54+00:00February 6th, 2018|

How diabetes affects prostate cancer prognosis

Men with type 2 diabetes are less likely to develop prostate cancer than patients without diabetes. However, the mortality rate is higher. Researchers were able to show that in the affected individuals the androgen receptor and the mitogenic forms of the insulin receptor were more strongly expressed. This could explain why patients with diabetes have a poorer prognosis for prostate cancer. Men with type 2 diabetes are less likely to develop prostate cancer than patients without diabetes. However, the mortality rate is higher. Researchers of the German Center for Diabetes Research (DZD) from Tübingen and experts of Helmholtz Zentrum München and the Urology Department of Tübingen University Hospital were able to show that in the affected individuals the androgen receptor and the mitogenic forms [...]

2018-02-01T08:03:09+00:00February 1st, 2018|

New study shows that some cases of aggressive prostate cancer may be linked to high-fat diet

Dr. Michael Lazar of California HIFU shares insights from a new study on prostate cancer, emphasizing that a healthy diet may contribute to prevention of the disease. There have been many discoveries recently that identify a link between a diet rich in fatty foods and increased risk of prostate cancer. The evidence continues to mount with the results of this new study investigating the effects of high-fat diets on certain prostate cancer tumors. Researchers at the Cancer Center at Beth Israel Deaconess Medical Center (BIDMC) discovered genetic mechanisms that promote cancer tumor metastasis, pointing to the typical Western high-fat diet as a key factor in driving that metastasis. The study was published this week in two journals; Nature Genetic and Nature Communications. It compared [...]

2018-01-23T09:50:13+00:00January 23rd, 2018|

New roadmap developed to genetically test for hereditary prostate cancer

A roadmap to help identify which men and their families may benefit from genetic evaluation for inherited prostate cancer has been developed by a team of researchers. To date, there have been few recommendations to guide physicians about when to offer men genetic consultation for prostate cancer risk. Now, an international and inter-specialty panel of experts convened at the Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University have developed a comprehensive set of recommendations. This consensus statement, published December 13th in the Journal of Clinical Oncology, will help physicians and stakeholders make sense of a rapidly evolving field of practice. "There is increasing recognition that some prostate cancers can be inherited. Genetic testing could provide men and their families with information about cancer [...]

2018-01-09T08:50:54+00:00January 9th, 2018|

#1 New Year’s Resolution for Men: Get screened for prostate cancer

#1 New Year’s Resolution for Men: Get screened for prostate cancer   Santa Rosa urologist and prostate cancer expert Dr. Michael Lazar provides an overview of prostate cancer screening options; says early detection saves lives. “Knowing the many options for treating prostate cancer is something all men at risk of developing the disease need to be informed about,” says Dr. Lazar. “Most men know about the unpleasant side effects that go along with traditional models of prostate cancer treatment, including urinary incontinence, bowel and erectile dysfunction. But some of the newer treatment modalities such as HIFU (high-intensity focused ultrasound) can only be undertaken at the early stages, when damage to surrounding tissue can best be mitigated, and most side effects eliminated.” Why Early [...]

2018-01-02T13:01:35+00:00January 2nd, 2018|

CMS Announces Increase To ASC Payment For HIFU Prostate Ablation

SonaCare Medical Reports That Medicare recognizes HIFU prostate ablation as a device-intensive procedure driving new ASC payment going into effect on or after October 1, 2017 CHARLOTTE, N.C., Sept. 20, 2017 SonaCare Medical, leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, is pleased to announce an increase in Medicare payment for prostate HIFU ablation in the Ambulatory Surgical Center (ASC) setting. In the October 2017 update of the ASC Payment System, the Centers for Medicare and Medicaid Services (CMS) indicated that the ASC payment status for C9747, the code used to bill for HIFU ablation of prostate tissue, now recognizes HIFU as a "device-intensive procedure". The new typical ASC payment level is $5,444.89, as compared to the approximately $4,000 payment amount which went [...]

2017-12-13T13:37:18+00:00November 14th, 2017|

New study reveals: Regret is lasting for many men who undergo traditional prostate cancer treatments

Responding to a recent review of patient comments spanning two decades Dr. Michael Lazar of California HIFU talks about the importance of informing prostate cancer patients about all available treatment options. A recent study revealed this month that as they get older, some men who have undergone treatment for prostate cancer come to regret the treatment decisions they made. This study reviewed the survey results of 934 men conducted at intervals of one, two, five, and 15 years after they were treated for prostate cancer. Most of the men (89%) were treated with surgery or radiation. Ultimately, 14.6% of the entire group expressed some regret over treatment results (16.6% of the radiation-treated men, 15% of the surgically-treated men, and 8.2% of the men treated conservatively). [...]

2017-12-13T13:37:18+00:00October 23rd, 2017|

New research could lead to reduction in recurrence of prostate cancer

Recurrence of prostate cancer could be reduced thanks to exciting new discovery Ground breaking research could reduce the recurrence of prostate cancer in males, a new study in the journal Nature Communications reports. During this in depth study, an international team of researchers led by British scientists investigated the impact of anti-hormone therapy on samples taken from patients with prostate cancer. Anti-hormone therapy is a commonly prescribed treatment for cancer of the prostate, which helps to reduce the levels of male hormones -- that stimulate cancer cells to grow -- in the gland. Researchers discovered that an inadvertent consequence of anti-hormone therapy treatment is the activation of the DNA repair enzyme, PARP. The triggering of PARP enables cancer cells to withstand anti-hormone therapy treatment, causing [...]

2017-12-13T13:37:18+00:00October 17th, 2017|

Prostate Cancer News: PSA screening significantly reduces the risk for death

After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. These findings suggest that current guidelines recommending against routine PSA-based screening may be revised. However, questions remain about how to implement screening so that the benefits outweigh the potential harms of over-diagnosis and overtreatment. The findings are published in Annals of Internal Medicine. Current guidelines from the United States Preventive Services Task Force (USPSTF) recommend against prostate-specific antigen (PSA) screening for prostate cancer because the evidence for the test showed very low probability that it would reduce [...]

2017-12-13T13:37:19+00:00October 11th, 2017|